Aimmune Therapeutics (NASDAQ:AIMT) had its buy rating reiterated by analysts at Cantor Fitzgerald. The analysts wrote, “Quick thoughts on today’s market reaction. Absent hearing pointed criticism of the PALISADE data, the market’s reaction befuddles us somewhat. We suppose AIMT owners could be taking profits, the stock is +50% since October 20, 2017, as compared with +1% for the NBI. Would-be investors might be disinclined to buy the stock on release of positive top-line results that were anticipated (in one fashion of another) and might desire a view of additional data. We are mindful, too, that the commercial launch of the product is likely 15-18 months hence.””
Alkermes (NASDAQ:ALKS) had its hold rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $50.00 target price on the stock. The analysts wrote, “Story still mainly about fate of ALKS 5461. With NDA recently filed, management believes a potential FDA Adcom and regulatory action could occur by YE18. The hiring of an additional 200 sales reps in 2018 disclosed on the 4Q17 results call seems aggressive to us given uncertainty about approval (unless intended to portray confidence), though we are mindful that they could be shifted to Vivitrol/Aristada. We suppose, too, that the expansion could be done in a step- wise manner.””
Polarityte (NASDAQ:COOL) had its buy rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $70.00 target price on the stock. The analysts wrote, “We believe the recent weakness in the shares reflect a misunderstanding of the company’s technology, associated with an erroneous publication regarding the company, the SkinTE product and the regulatory requirements for registration.””
Domino's Pizza (NYSE:DPZ) had its overweight rating reaffirmed by analysts at Stephens. The firm currently has a $245.00 price target on the stock, up from their previous price target of $220.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.
Fogo De Chao (NASDAQ:FOGO) was downgraded by analysts at Piper Jaffray Companies from an overweight rating to a neutral rating.
Sidoti initiated coverage on shares of Federal Signal (NYSE:FSS). The firm issued a neutral rating on the stock.
Roku (NASDAQ:ROKU) had its positive rating reaffirmed by analysts at Citigroup Inc.
Safety Income & Growth (NYSE:SAFE) had its buy rating reaffirmed by analysts at Ladenburg Thalmann Financial Services. The firm currently has a $20.00 target price on the stock, down from their previous target price of $22.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.
Taiwan Semiconductor Mfg. (NYSE:TSM) was upgraded by analysts at Credit Suisse Group AG from a neutral rating to an outperform rating.
Wal-Mart Stores (NYSE:WMT) had its outperform rating reiterated by analysts at Robert W. Baird. They currently have a $105.00 target price on the stock, down from their previous target price of $110.00.
Xencor (NASDAQ:XNCR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.